Eli Lilly: Plans to invest a total of $3 billion over the next ten years to fully expand supply chain capacity in China

K-LinePoet

2026-03-27 14:35:51

Abstract generation in progress

On March 11, Eli Lilly (LLY.US) announced that it plans to invest a total of $3 billion over the next decade to fully expand its supply-chain production capacity in China, building a local production and supply system for oral solid dosage forms, and focusing on scaling up the production capacity for its first orally administered small-molecule GLP-1 receptor agonist, orforglipron, that has been submitted for approval and registration.

Eli Lilly China had already filed a marketing application with the National Medical Products Administration at the end of 2025 for orforglipron to treat type 2 diabetes and obesity.

This investment will use a model that combines internal expansion with external collaboration: on the one hand, leveraging the technological and talent advantages of Eli Lilly’s Suzhou plant to strengthen capacity coordination; on the other hand, partnering with multiple local manufacturing companies to unlock incremental production capacity.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes